Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. (2022)

First Author: Fletcher T

Attributed to: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.21203/rs.3.rs-1835695/v1

Publication URI: http://dx.doi.org/10.21203/rs.3.rs-1835695/v1

Type: Preprint